ArticleCancer management and research2019
A Novel lncRNA MYOSLID/miR-1286/RAB13 Axis Plays a Critical Role in Osteosarcoma Progression.
Article in Cancer management and research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 33 citations in OpenAlex.
- Review
- miR-1286, a Tumor Suppressor of Gastric Cancer, Serves as a Promising Biomarker for Screening Gastric Cancer from Gastritis.Biochemical genetics · 2024Article
- Osteosarcoma in a ceRNET perspective.Journal of biomedical science · 2024Review
- Prognostic cellular senescence-related lncRNAs patterns to predict clinical outcome and immune response in colon cancer.Frontiers in immunology · 2024Article
- Long non-coding HOXA-AS3 contributes to osteosarcoma progression through the miR-1286/TEAD1 axis.Journal of orthopaedic surgery and research · 2023Article
- Role of a lipid metabolism-related lncRNA signature in risk stratification and immune microenvironment for colon cancer.BMC medical genomics · 2022Article
- Circ_0051079 functions as an oncogenic regulator in osteosarcoma by leading to MAFB expression upregulation by competitively interacting with miR-1286.Journal of orthopaedic surgery and research · 2022Article
- Article
- lncRNA BZRAP1-AS1 alleviates rheumatoid arthritis by regulating miR-1286/COL5A2 axis.Immunity, inflammation and disease · 2022Article
- Identification of a ferroptosis-related long noncoding RNA signature with a prognostic value in adrenocortical carcinoma.Frontiers in genetics · 2022Article
- Comprehensive Analysis of Pyroptosis-Related Long Noncoding RNA Immune Infiltration and Prediction of Prognosis in Patients with Colon Cancer.Journal of oncology · 2022Article
- Qualification of Necroptosis-Related lncRNA to Forecast the Treatment Outcome, Immune Response, and Therapeutic Effect of Kidney Renal Clear Cell Carcinoma.Journal of oncology · 2022Article
- Silencing of circHIPK3 Sensitizes Paclitaxel-Resistant Breast Cancer Cells to Chemotherapy by Regulating HK2 Through Targeting miR-1286.Cancer management and research · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOsteosarcoma (OS) is a quite malignant bone cancer. However, how long noncoding RNA (lncRNA) regulates OS progression remains poorly investigated. The present study aims to illustrate the potential functions of lncRNA MYOSLID in the regulation of OS progression.
methodsThe expression of YOSLID, miR-1286 and RAB13 was analyzed by qRT-PCR. Cell proliferation was determined via CCK8 and colony formation assays. Transwell assay was used to examine migration and invasion. The luciferase reporter assay, RNA pulldown and RNA immunoprecipitation (RIP) assays were utilized to detect the interactions among MYOSLID, miR-1286 and RAB13.
resultsThe expression of MYOSLID was upregulated in OS tissues and cell lines. MYOSLID overexpression predicted poor prognosis in OS patients. MYOSLID knockdown suppressed proliferation, migration and invasion of OS cells. MYOSLID was the sponge for miR-1286 and inhibited its expression while miR-1286 targeted RAB13 directly. MYOSLID promoted RAB13 expression via sponging miR-1286.
conclusionOur work demonstrated that the MYOSLID/miR-1286/RAB13 axis is a novel regulatory signaling in promoting OS progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.